It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Paige Breast Lymph Node designed to enhance diagnostic accuracy and confidence detecting breast cancer metastases of any size in lymph node tissue
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Tislelizumab is now approved for seven indications in China
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Subscribe To Our Newsletter & Stay Updated
